Loop diuretic treatment: time for new options


Cite item

Full Text

Abstract

Обсуждаются современные подходы к длительному лечению петлевыми диуретиками и значение отдельных представителей этого класса препаратов, в частности торасемида

About the authors

- -

References

  1. Bleich M., Greger R. Mechanism of action of diuretics. Kidney Int. 1997;51(Suppl. 59):S11-S15.
  2. Suki W.N. Use of diuretics in chronic renal failure. Kidney Int. 1997;51(Suppl. 59):S33-S35.
  3. Dunn C.J., Fitton A., Brogden R.N. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49(1):121-42.
  4. Tesar V., Zima T., Kalousova M. Pathobiochemistry of nephrotic syndrome. Adv. Clin. Chem. 2003;37:173-218.
  5. Friedley H., Buckley M., Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991;41(1):81-103.
  6. Vargo D.L., Kramer W.G., Black P.K., et al. Bioavailability, pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with congestive heart failure. Clin. Pahrmacol. Ther. 1995;57:601-09.
  7. Kim E.J., Lee M.G. Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. Biopharm. Drug Dispos. 2003;24(1):27-35.
  8. Gerbes A.L., Bertheau-Reitha U., Falkner C., et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. J. Hepatol. 1993;17(3):353-58.
  9. Kramer W.G. Effect of food on the pharmacokinetics and pharmacodynamics of torsemide. Am. J. Ther. 1995;2(7):499-503.
  10. Boesken W.H., Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin. Nephrol. 1997;48(1):22-28.
  11. Fliser D., Schröter M., Neubeck M., et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46(2):482-88.
  12. Gehr T.W., Rudy D.W., Matzke G.R., et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 1994;56(1):31-38.
  13. Whelton A., Smith W.B., Wallin J.D., et al. Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency. Am. J. Ther. 1996;3(11):743-49.
  14. Risler T., Kramer B., Müller G.A. The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide. Drugs. 1991;41(Suppl. 3):69-79.
  15. Shilliday I.R., Quinn K.J., Allison M.E. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol. Dial. Transplant. 1997;12(12):2592-96.
  16. Bagshaw S.M., Delaney A., Haase M., et al. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit. Care Resusc. 2007;9(1):60-68.
  17. Vargas Hein O., Staegemann M., Wagner D., et al. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Ren. Fail. 2005;27(4):385-92.
  18. Vormfelde S.V., Schirmer M., Hagos Y., et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br. J. Clin. Pharmacol. 2006;62(3):323-35.
  19. Brater D.C. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996;14(2):104-20.
  20. Patterson J.H., Adams K.F. Jr., Applefeld M.M., et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994;14(5):514-21.
  21. Paterna S., Fasullo S., Di Pasquale P. High-dose torasemide is equivalent to high-dose furosemide with hypertonic saline in the treatment of refractory congestive heart failure. Clin. Drug Investig. 2005;25(3):165-73.
  22. Murray M.D., Deer M.M., Ferguson J.A., et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am. J. Med. 2001;111(7):513-20.
  23. Cosin J., Diez J., TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002;4(4):507-13.
  24. Kasama S., Toyama T., Hatori T., et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92(10):1434-40.
  25. Goodfriend T.L., Ball D.L., Oelkers W., et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63(3):PL45-PL50.
  26. Struthers A.D. Impact of aldosterone on vascular pathophysiology. Congest. Heart Fail. 2002;8:18-22.
  27. Auchus R.A. Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr. Opin. Nephrol. Hypertens. 2003;12:153-58.
  28. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999;341:709-17.
  29. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003;348:1309-21.
  30. Yamato M., Sasaki T., Honda M., et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003;67:384-90.
  31. Harada K., Izawa H., Nishizawa T., et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J. Cardiovasc. Pharmacol. 2009;53(6):468-73.
  32. Lopez B., Querejeta R., Gonzalez A. et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 2004;43(11):2028-35.
  33. Lopez B., Gonzalez A., Beaumont J., et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007;50(9):859-67.
  34. Veeraveedu P.T., Watanabe K., Ma M., et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2007;23:143-48.
  35. Reyes A.J., Leary W.P. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations. Cardiovasc. Drugs Ther. 1993;(7 Suppl. 1):29-44.
  36. Lopez B., Gonzalez A., Hermida N., et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int. 2008;(111 Suppl.):S19-S23.
  37. Knauf H., Mutschler E., Velazquez H., et al. Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur. J. Clin. Pharmacol. 2009;65(5):465-72.
  38. Franse L.V., Pahor M., Di Bari M., et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025-30.
  39. Muller K., Gamba G., Jaquet F., et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur. J. Heart Fail. 2003;5(6):793-801.
  40. Stroupe K.T., Forthofer M.M., Brater D.C., et al. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17(5):429-40.
  41. The ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 2005;26(11):1115-40.
  42. Achhammer I., Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991;41(Suppl. 3):80-91.
  43. Vasavada N., Saha C., Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003;64(2):632-40.
  44. Lyseng-Williamson K.A. Torasemide prolonged release. Drugs. 2009;69(10):1363-72.
  45. Díez J., Coca A., de Teresa E., et al.; TORAFIC Investigators Group. Collaborators (22) TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. Expert. Rev. Cardiovasc. Ther. 2009;7(8):897-904.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies